VANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Consumer healthcare markets hit a massive $362 billion entering 2026, but smart money is shifting toward regulatory certainty rather than just market size[1]. Modern health organizations are using aggressive buyouts as a primary 2026 strategy to secure high-tech efficiency while navigating intense federal scrutiny and capital limits[2]. In this high-stakes environment, companies with a clear and proven path through federal guidelines are capturing the most attention, including Doseology Sciences Inc. (CSE: MOOD) (OTCPK:DOSEF) (FSE: VU70), Canopy Growth (NASDAQ: CGC) (TSX: WEED), Definium Therapeutics (formerly Mind Medicine (MindMed)) (NASDAQ: DFTX), Lipocine (NASDAQ: LPCN), and Keurig Dr Pepper (NASDAQ: KDP).
Financial leaders report that 80% of executives now view regulatory factors as the main force shaping their 2026 business plans[3]. This shift has turned compliance from a back-office cost into a powerful competitive edge that can determine if a company thrives or fails. Industry analysts expect a 12% jump in merger activity as companies consolidate to handle rising demand and cost pressures. Success in these billion-dollar deals now depends entirely on deep diligence into federal risks, making execution the ultimate value driver for the current investment cycle[4].
Doseology Sciences Inc. (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70) is a biotechnology company developing oral delivery platforms for modern stimulants, positioning itself within a consumer shift away from traditional energy drinks, vapes, and cigarettes toward formats designed for precision, control, and convenience.
In today's regulated consumer product landscape, science is no longer optional. Whether addressing harm reduction or supporting credible product claims, both consumers and regulators demand rigorous validation. For companies operating in nicotine, stimulant, and functional ingredient categories, navigating FDA expectations and Pre-market Tobacco Product Application (PMTA) pathways represents the difference between market access and regulatory exclusion.
On January 9, 2026, the Kelowna, British Columbia-based company announced a strategic partnership with McKinney Regulatory Science Advisors, a premier FDA regulatory consulting firm specializing in nicotine and reduced-risk consumer products. The collaboration marks a pivotal advancement for Doseology, transitioning the company toward regulatory execution and commercial readiness.
"Doseology is committed to leading with science and innovation in the oral pouch category," said Tim Corkum, President and COO of Doseology. "Engaging McKinney, a leader in regulatory science, ensures that our product development is not only innovative but also strategically aligned with regulatory expectations. This partnership underscores our dedication to building a defensible, regulatory-ready platform that prioritizes dose consistency and consumer safety."
McKinney's comprehensive guidance will encompass formulation strategy, data generation, PMTA preparation, and post-market compliance, positioning Doseology as a frontrunner in delivering differentiated, IP and trade secret protected oral pouch products to regulated markets. The firm will conduct regulatory landscape assessments for stimulant, nicotine, and nicotine-alternative pouch formats across relevant jurisdictions, define specific data and testing requirements to support anticipated claims and submissions, advise on labeling and packaging compliance, and develop pre-submission engagement plans with regulators.
McKinney recently played a central role in supporting Altria Group Inc.'s successful FDA authorization for its ON! nicotine pouch portfolio, demonstrating the caliber of expertise now aligned with Doseology's regulatory pathway.
The partnership is expected to expedite Doseology's navigation of FDA requirements while strengthening intellectual property protection through aligned formulation and testing strategies. With regulatory strategy now formalized, manufacturing infrastructure secured through its Florida-based subsidiary, and commercial leadership in place under former Swedish Match AB and Philip Morris International Inc. executive Patrick Sills, Doseology is advancing toward market entry within a global pouch market expected to exceed US$69.46 billion by 2032.
CONTINUED... Read this and more news for Doseology Sciences at:
https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/
Canopy Growth (NASDAQ: CGC) (TSX: WEED) has entered a definitive arrangement agreement to acquire all issued and outstanding common shares of MTL Cannabis Corp., with each shareholder receiving 0.32 of a Canopy Growth share and $0.144 in cash per share in a transaction valued at approximately $125 million on a fully-diluted equity basis and approximately $179 million on an enterprise value basis. The highly accretive business combination is expected to generate significant run-rate synergies of approximately $10 million within 18 months, strengthening Canopy Growth's presence in Québec with an opportunity to expand national distribution of MTL's high-quality budtender-recommended product portfolio recognized as Canada's number one budtender-recommended brand in a 2024 Brightfield Study.
"MTL brings skilled operators, strong brands, and a profitable business that will strengthen our leadership in Canada's medical market and deepens our presence in key Canadian adult-use markets, including Québec," said Luc Mongeau, CEO of Canopy Growth. "Their cultivation expertise, combined with our national scale, positions us to improve product quality, expand supply, and accelerate our path to profitable growth."
The transaction requires approval of at least two-thirds of votes cast by MTL shareholders at a special meeting expected in the first calendar quarter of 2026. Canopy Growth has secured irrevocable voting support agreements with certain directors, officers and key shareholders representing approximately 75% of issued and outstanding MTL shares, with closing expected before the end of February 2026 subject to regulatory approvals including TSX approval and Competition Act Canada approval.
Definium Therapeutics (formerly Mind Medicine (MindMed)) (NASDAQ: DFTX) has unveiled its new brand marking a decisive step forward as the company leads psychiatry toward transformation built on strong clinical evidence and scientific rigor, with three Phase 3 readouts expected in 2026 including the Voyage study for DT120 ODT in generalized anxiety disorder in second quarter 2026. The company's late-stage pipeline includes four Phase 3 trials evaluating DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD, with Definium positioned to deliver data in the two largest psychiatric markets affecting over 50 million people in the U.S.
"Definium Therapeutics reflects the core of who we've always been and where we're headed - disciplined execution, scientific leadership, and a vision to develop accessible treatments that can unlock healing at scale," said Rob Barrow, CEO of Definium Therapeutics. "We are unwavering in our mission to forge a new era of psychiatry by applying scientific rigor to psychedelics."
Expected milestones in 2026 include an analyst day highlighting pivotal programs in second quarter, topline data from Panorama in second half for GAD, topline data from Emerge mid-year for MDD, and initiation of Ascend mid-year for MDD. The company's ticker symbol changed to DFTX effective at market open on January 13, 2026, as Definium continues advancing its early-stage pipeline with DT402 in autism spectrum disorder.
Lipocine (NASDAQ: LPCN) reported encouraging progress following the second independent Data Safety Monitoring Board review of its Phase 3 clinical trial evaluating LPCN 1154 for postpartum depression. The DSMB recommended the trial continue as planned without modification based on safety data from 82 randomized participants, with no treatment discontinuations, drug-related serious adverse events, excessive sedation, or loss of consciousness reported.
"The data generated to date reinforces our confidence in the safety profile of LPCN 1154," said Mahesh Patel, CEO of Lipocine. "We believe LPCN 1154's target profile, including superior tolerability, rapid therapeutic benefit, and a short 48-hour treatment course, has the potential to establish a new and improved treatment paradigm for PPD."
The study is no longer screening new participants, with enrollment continuing for participants meeting eligibility criteria. Lipocine remains on track to report topline safety and efficacy results early in the second quarter of 2026, supporting a 505(b)(2) NDA submission in 2026.
Keurig Dr Pepper (NASDAQ: KDP) has launched a public offer to acquire all outstanding shares of JDE Peet's N.V. at EUR 31.85 per share in cash, with the offer memorandum approved by Dutch financial authorities. The board of JDE Peet's unanimously supports the recommended offer, with approximately 69% of shareholders including Acorn Holdings B.V. and board members having irrevocably undertaken to tender their shares during the offer period running from January 16 to March 27, 2026.
Following the acquisition, KDP plans to separate into two independent U.S.-listed publicly traded companies, creating a scaled growth challenger in North America's refreshment beverages market and a global coffee leader serving over 100 countries with an unparalleled brand portfolio across all coffee segments. All required competition clearances have been obtained, with closing expected early in the second quarter of 2026 subject to a minimum acceptance threshold of 95% of shares, or 80% if shareholders approve certain post-closing restructuring measures at the extraordinary general meeting scheduled for March 2, 2026.
Article Source: https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/
CONTACT:
Equity Insider
info@equity-insider.com
(604) 265-2873
DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). "). This article is being distributed for Maynard Communications (“MAY”), who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Doseology Sciences. Inc. advertising or digital media, but the owner/operators of MIQ also co-owns MAY. There may be 3rd parties who may have shares of Doseology Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Doseology Sciences Inc., which were purchased as a part of a private placement. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Doseology Sciences Inc.; this is a paid advertisement, we currently own shares of Doseology Sciences Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
SOURCES CITED:
- https://www.towardshealthcare.com/insights/consumer-healthcare-market-sizing
- https://www.ey.com/en_us/newsroom/2025/12/ey-us-identifies-eight-health-trends-for-2026
- https://www.ey.com/us/en/insights/strategy/healthcare-sector-outlook-in-2026
- https://digitaldefynd.com/IQ/interesting-mergers-and-acquisitions-facts-and-statistics/
